Zucara Therapeutics, an adMare & TIAP Spin-off Company, Announces $21M Series A Financing
The proceeds from the financing will fund Phase 1 & Phase 2 clinical trials of ZT-01, Zucara’s first-in-class drug candidate designed...
Read the article
adMare and BELLUS Health Close Transaction for Intellectual Property Rights to P2X3 Platform
adMare BioInnovations & BELLUS have closed an agreement under which BELLUS has acquired full ownership of intellectual property previously licensed from...
Read the article
adMare Portfolio Company Receives FDA 510(k) Clearance
adMare BioInnovations Portfolio Company SoundBite Receives FDA 510(k) Clearance of the SoundBite™ Crossing System – Peripheral MONTREAL – SoundBite Medical Solutions...
Read the article
adMare BioInnovations & Accel-Rx Unite to Advance the Canadian Life Sciences Sector
The addition of Accel-Rx’s expertise in seed stage investments and entrepreneur development strengthens adMare’s position as a single-stop destination with the...
Read the article